Abstract: A composite material which has excellent ballistic performance and has improved flexibility. Surprisingly, it has been found that a combination of poly(alpha-olefin) fiber and matrix resin provides these desirable product features. The resin matrix is a block copolymer of a conjugated diene and a vinyl aromatic monomer, preferably a styrene-isoprene-styrene block copolymer, that is applied as an aqueous composition. The fiber has a tenacity of at least about 35 g/d and a tensile modulus of at least about 1200 g/d. The composite has a total density equal to or less than about 100 g/m2 and a stiffness of less than about 2.5 pounds (1.14 kg) for a two layer structure of the composite, and a total areal density equal to or less than about 190 g/m2 and a stiffness of less than about 3.0 pounds (1.36 kg) for a four layer structure of the composite. The Peel Strength for a two layer structure of less than about 1.0 pounds (0.45 kg) for a two layer structure of the composite, and less than about 0.7 pounds (0.

Abstract: The invention relates in general to 7,9-dihydro-purin-8-one and related compounds that show broad utility, e.g., in inhibiting heat shock protein 90 (HSP90) to thereby treat or prevent HSP90-mediated diseases.

Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Abstract: A method of making a ballistic resistant composite material having improved resistance to high energy rifle bullets and the like. The method comprises providing at least one fibrous layer comprising a network of high tenacity aramid fibers. The fibrous layer is coated with a thermoplastic polyurethane resin. The coated fibrous layer is molded at a pressure of at least about 1,500 psi (10.3 MPa). Preferably, a plurality of fibrous layers are employed, each of which is formed from unidirectionally oriented aramid fibers in a thermoplastic polyurethane resin matrix. Adjacent fibrous layers are preferably oriented at 90° with respect to each other.

Abstract: The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Abstract: Fabric laminates having superior resistance to penetration of fragments, such as shrapnel. The fabrics are formed of high-strength fibers consolidated with from about 7% to about 15% by weight of an elastomeric matrix composition, and in combination with protective layers of a polymer film on each surface of the fabric. The fabrics achieve a significant improvement in fragment resistance compared to fabrics of the prior art, while also maintaining excellent ballistic resistant properties.

Abstract: Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

Abstract: The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein W, X, Y, Z, R1, R2a, R2b, and Rx, R8 and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Abstract: A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: wherein: R1 is halogen, —OR1, —SR11 or lower alkyl; R2 is —NHR8; R3 is selected from the group consisting of hydrogen, halogen, —SR8, —OR8, —CN, —C(O)R9, —CO2H, —NO2, —NR8R10, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R4 is —CHR12—, —C(O), —C(S), —S(O)—, or —SO2—; R5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents.

Abstract: Documents are grouped into a plurality of subjects. For documents associated with each subject, a document hierarchy is established that includes a plurality of hierarchical levels. A three-dimensional landscape defined by x, y and z orthogonal axes is displayed on a screen, and a plurality of document stacks are arranged in the landscape. Each document stack in the landscape corresponds to a subject, and has a plurality of layers arranged perpendicular to the length of the stack. Each layer in each document stack corresponds to one of the hierarchical levels of the hierarchy established for the subject corresponding to the stack. Images representing documents assigned to each level of the hierarchy are displayed in the layer of the stack corresponding to such level. A user navigates among the document images displayed in the landscape using a cursor.

Abstract: Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Abstract: The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Abstract: An improved load leveling yarn has a force-displacement profile that maintains desirable properties of previously known yarns (as exemplified in U.S. Pat. No. 5,830,811), but exhibits a lower elongation at a stress that is greater than the IBS but less than or equal to 1.8 grams/denier. Especially preferred yarns are produced from PET with an IV of greater than 0.9 and epsilon caprolactone (at a ratio of about 90:10) under copolymerization conditions that allow reaction of at least 95% of the added epsilon caprolactone. Such yarns can then be formed into a web to form specific products, and especially seat belts.

Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2, Rx, R8, R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Abstract: An improved load leveling yarn has a force-displacement profile that maintains desirable properties of previously known yarns (as exemplified in U.S. Pat. No. 5,830,811), but exhibits a lower elongation at a stress that is greater than the IBS but less than or equal to 1.8 grams/denier. Especially preferred yarns are produced from PET with an IV of greater than 0.9 and epsilon caprolactone (at a ratio of about 90:10) under copolymerization conditions that allow reaction of at least 95% of the added epsilon caprolactone. Such yarns can then be formed into a web to form specific products, and especially seat belts.

Abstract: Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

Abstract: Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.

Abstract: A voltage detection circuit, in conjunction with a power supply system for ringing voltage generation in a remote telecommunications unit, monitors the operating voltage level of the remote unit and, when an undervoltage condition is detected, causes a ringing reference-signal generator to collapse the reference (AC) sine wave into a fixed (DC) state and holds it in this state for a preselected time, thereby substantially reducing the ringing-signal current load and allowing the operating voltage level to restore. The features of the invention allow for continued processing of calls in progress and for incoming call completion during an undervoltage condition. The increased reliability and integrity of the power supply system allows for extended power supply feeder distance to the remote telecommunications unit.